Jinshi Asia Pharmaceutical (300434.SZ) announced the results for the first three quarters, with net profit of 142 million yuan to mother, an increase of 46.33% over the previous year

According to the Zhitong Finance App, Jinshi Pharmaceutical (300434.SZ) released its report for the third quarter of 2026. In the first three quarters, the company achieved revenue of 711 million yuan, an increase of 0.30% over the previous year. Net profit attributable to shareholders of listed companies was 142 million yuan, an increase of 46.33% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $129 million, an increase of 63.57% over the previous year.